Pedro Exman MD, PhD All great points, my friend.

I guess that the main counter arguments are that most of the benefit from anthracyclines in the trial is seen in TNBC (do we need them for HR+?), that despite better RFI, OS is the same (do the added leukemias & non-BC deaths jeopardize the…

Important update of the ABC trials. With 6.9y of follow up, adjuvant AC-T had a small RFI benefit over TC, restricted to triple-negative tumors. No OS benefit by adding anthracyclines, but a major increase in leukemias (7 vs 1) & non-BC deaths (62 vs 34). ascopubs.org/doi/10.1200/JC…

Please join us Jan 19 for the next installment of our EMBRACE Program virtual forum, designed for patients living with MBC. It will be a treat to hear Harold J. Burstein, MD, PhD, FASCO from Dana-Farber’s Breast Oncology Center review updates from the 2023 San Antonio Breast Cancer Symposium!

Thank you Harold J. Burstein, MD, PhD, FASCO for 10 years overseeing #JCO ’s Oncology Grand Rounds section!

This supports increasing number of TNBC trials including patients with ER/PR <10% instead of classically <1%, which biologically makes complete sense

KATHERINE trial update:
-impressive 13.7% absolute gain in IDFS at 7y with TDM1
-4.7% absolute gain in OS, with further f/u ongoing
-half of distant events occur in CNS - reinforces importance of COMPASS-RD clinical trial testing TDM1-tucatinib
#SABCS23

Part of the colleagues who paticipate in this brazilian research group that studies breast cancer patients survivors

❓Should we be dissecting axilla in pts with residual ITCs after neoadjuvant chemo?

▪️Additional LN found in 30% of cases 😳

👏 Despite this, no diff at 5 years among that had axillary dissection or not.

#SABCS23 SABCS #bcsm

Presented today at #SABCS23 and published in JAMA results of our study showing the feasibility and safety of #pregnancy after #BreastCancer in young #BRCA carriers

OncoAlert SABCS AACR Università di Genova Ospedale San Martino Genova #bcsm

Link here:
jamanetwork.com/journals/jama/…

THE BIGGEST TWEET from OncoAlert 🚨 #SABCS23

With a Concomitant publication in JAMA

OUR OncoAlert 🚨 #BreastCancer SuperStar⭐️
Matteo Lambertini, MD PhD 🇮🇹presenting on:
Pregnancy After Breast Cancer in Young BRCA Carriers

Link
jamanetwork.com/journals/jama/…

Kudos from your…

KUDOS to my Dear Friend Matteo Lambertini, MD PhD

Just Presented at #SABCS23 & with a Simultaneous JAMA Publication

'Pregnancy After Breast Cancer in Young BRCA Carriers'

jamanetwork.com/journals/jama/…

Dec 7th has arrived! You'll find our poster detailing the impact of performing Prosigna on upfront core biopsies on treatment decision-making at Hall 2-3 from noon to 2 pm. Thx once again to all the co-authors and to my Dana-Farber’s Breast Oncology Center mentor, Dr. Sara Tolaney !

Incredible effort to look at pregnancy and outcomes in pts with BRCAm

Pregnancy without impact on recurrence particularly in pts with BRCA1m

@Oncoalert #SABCS23 Matteo Lambertini, MD PhD

TROPION BREAST01: Dat0-DXd vs chemo in mHR+ 1-2 prior lines of chemo
mPFS 6.9 vs 4.5 mo HR 0.64
Time to sub tx 8.2 vs 5.0 mo
n=58 pts w/brain mets at baseline, similar benefit seen
Fewer g≥3 AEs with Dato-Dxd: 21% vs 45%
Delayed TTD in QOL with Dato

#SABCS23 OncoAlert

O trabalho tem como autor sênior o oncologista Pedro Exman, e mostra o impacto positivo da chegada de T-DXd e da nova classificação de HER2.
📲Leia mais: tinyurl.com/3u78jbrt

#oncologia #oncology #cancer #onconews #SABCS23

Excited to present the results of #AMYCA study at #SABCS23 : use of #AMH at diagnosis and/or after chemotherapy may help predicting permanent loss of ovarian function…relevant question for optimizing endocrine therapy choices
Ines Vaz Luis Eric Winer, MD OncoAlert SABCS

What do real-world data say about ADC sequencing and resistance? Dr. Ana Garrido-Castro Dana-Farber’s Breast Oncology Center beautifully summarizes the existing data and stresses the importance of prospective trials and translational science to move the field further forward. #SABCS23

Congrats to Dana-Farber's Sara Tolaney, MD, MPH (@stolaney1) on receiving the Susan G. Komen 2023 Rising Star Researcher Award. #SABCS23 🎉 🎉 🎉